The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.
 
Mohammad O. Atiq
Travel, Accommodations, Expenses - Agios; Alnylam (I); Astellas Pharma; AstraZeneca (I); Celgene; Daiichi Sankyo Inc. (I); Foundation Medicine (I); Genentech (I); Gilead Sciences (I); Incyte; Jazz Pharmaceuticals; Pfizer; Pfizer (I); Rigel; Rigel
 
Elias Bin Aris Chandran
Stock and Other Ownership Interests - Pacific Edge Biotechnology
 
Luke Meininger
No Relationships to Disclose
 
Fatima Karzai
No Relationships to Disclose
 
Marijo Bilusic
Research Funding - Bavarian Nordic (Inst); ImmunityBio (Inst); NextCure (Inst)
 
Jennifer L. Marte
No Relationships to Disclose
 
Philip M. Arlen
Employment - Precision Biologics
Leadership - Precision Biologics
Stock and Other Ownership Interests - Precision Biologics
 
Lisa M. Cordes
No Relationships to Disclose
 
Julius Strauss
Research Funding - Bavarian Nordic (Inst); EMD Serono (Inst); ImmunityBio (Inst); PDS Biotechnology (Inst); Precigen (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on NIH pending patent (Inst)
 
Jason Redman
No Relationships to Disclose
 
Charalampos S. Floudas
No Relationships to Disclose
 
Danielle M. Pastor
No Relationships to Disclose
 
Helen Owens
No Relationships to Disclose
 
Amy Hankin
Stock and Other Ownership Interests - Amgen; Medtronic
 
Monique Williams
No Relationships to Disclose
 
William Douglas Figg
Research Funding - Astellas Pharma (Inst); Biocompatibles (Inst); Celgene (Inst); Nerviano Medical Sciences (Inst); NovaRX (Inst); Pfizer (Inst); TRACON Pharma (Inst)
 
William L. Dahut
Leadership - Dexcom (I)
Stock and Other Ownership Interests - Dexcom (I)
 
Jeffrey Schlom
Research Funding - Bavarian Nordic (Inst); EMD Serono/Merck (Inst); ImmunityBio (Inst); Incyte (Inst); NextCure (Inst); PDS Biotechnology (Inst); Precigen (Inst)
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); ImmunityBio (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH HPV+ MALIGNANCIES Publication number: 20200062849 Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subje
 
Ravi Amrit Madan
Speakers' Bureau - Boehringer Ingelheim (I); Janssen (I); Pfizer (I)
Research Funding - Bayer